Eli Lilly Just Raised Its 2026 Revenue Forecast by $5.5 Billion. Is the Stock Still a Buy?
The stock is expensive, but the potential market for GLP-1 drugs is likely much larger than forecast.
Full story
Read the full story at The Motley Fool ↗
Continue reading this story on The Motley Fool, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.
